Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones

Virology

Volumn 364, Issue 1, 2007, Pages 155-168

  Mylin, Lawrence M ^a,b   Schell, Todd D ^a   Epler, Melanie ^a   Kusuma, Caroline ^b   Assis, David ^b   Matsko, Chelsea ^b   Smith, Alexandra ^b   Allebach, April ^b   Tevethia, Satvir S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b MESSIAH COLLEGE   (United States)

Author keywords

CD8+ T lymphocyte; CTL clone; CTL epitope; CTL escape variant; Cytotoxicity; Epitope mutation; SV40 Tag

Indexed keywords

EPITOPE; TUMOR ANTIGEN; VIRUS T ANTIGEN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL CLONE; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; EPITOPE MAPPING; IN VITRO STUDY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIMIAN VIRUS 40;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BASE SEQUENCE; CELL LINE, TRANSFORMED; DNA, VIRAL; EPITOPES; IMMUNITY, CELLULAR; MICE; MUTATION; SIMIAN VIRUS 40; T-LYMPHOCYTES, CYTOTOXIC; VARIATION (GENETICS);

SIMIAN VIRUS 40;

EID: 34249671271     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.02.007     Document Type: Article

References (64)

1. Akilesh S., Dudley M.E., Eden P.A., and Roopenian D.C. Efficient chromosomal mapping of a methylcholanthrene-induced tumor antigen by CTL immunoselection. J. Immunol. 167 (2001) 5143-5149
2. Bai X.F., Liu J., Li O., Zheng P., and Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J. Clin. Invest. 111 10 (2003) 1487-1496
3. Bergmann C.C., Yao Q., Ho C.K., and Buckwold S.L. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J. Immunol. 157 (1996) 3242-3249
4. Boon T., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183 (1996) 725-729
5. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P., and Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12 (1994) 337
6. Borrow P., and Shaw G.M. Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?. Immunol. Rev. 164 (1998) 37-51
7. Brander C., Yang O.O., Jones N.G., Lee Y., Goulder P., Johnson R.P., Trocha A., Colbert D., Hay C., Buchbinder S., Bergmann C.C., Zweerink H.J., Wolinsky S., Blattner W.A., Kalams S.A., and Walker B.D. Efficient processing of the immunodominant HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. J. Virol. 73 (1999) 10191-10198
8. Campbell A.E., Foley F.L., and Tevethia S.S. Demonstration of multiple antigenic sites of the SV40 transplantation rejection antigen by using cytotoxic T lymphocyte clones. J. Immunol. 130 1 (1983) 490-492
9. Charini W.A., Nuroda M.J., Schmitz J.E., Beaudry K.R., Lin W., Lifton M.A., Krivulka G.R., Necker A., and Letvin N.L. Clonally diverse CTL response to a dominant viral epitope recognizes potential epitope variants. J. Immunol. 167 (2001) 4996-5003
10. Coulie P.G., Karanikas V., Colau D., Lurquin C., Landry C., Marchand M., Dorval T., Brichard V., and Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. U.S.A. 98 18 (2001) 10290-10295
11. b-restricted epitopes, on antigen presentation and recognition by cytotoxic T lymphocyte clones. J. Immunol. 148 10 (1992) 3012-3020
12. Deckhut A.M., Tevethia M.J., Haggerty S., Frisque R.J., and Tevethia S.S. Localization of common cytotoxic T lymphocyte recognition epitopes on Simian Papovavirus SV40 and human Papovavirus JC virus T antigens. Virology 183 (1991) 122-132
13. b-restricted cytotoxic T-lymphocyte recognition epitopes in Simian virus 40 T antigen. J. Virol. 66 1 (1992) 440-447
14. Del Val M., Schlicht H.J., Ruppert T., Reddehase M.J., and Kosinowski U.H. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66 (1991) 1145-1153
15. Dudley M.E., and Roopenian D.C. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med. 184 (1996) 441-447
16. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 5594 (2002) 850-854
17. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 11 (2002) 991-998
18. Fanning E. Simian virus 40 large T antigen; the puzzle, the pieces, and the emerging picture. J. Virol. 66 (1992) 1289-1293
19. Fu T.-M., Mylin L.M., Schell T.D., Bacik I., Russ G., Yewdell J.W., Bennink J.R., and Tevethia S.S. An endoplasmic reticulum targeting signal sequence enhances the immunogenicity of an immunorecessive Simian virus 40 T antigen cytotoxic T lymphocyte epitope. J. Virol. 72 (1998) 1469-1481
20. Gairin J.E., and Oldstone M.B.A. Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: implications for control of viral disease. J. Virol. 66 (1992) 6755-6762
21. Hahn Y.S., Hahn C.S., Braciale V.L., Braciale T.J., and Rice C.M. CD8+ T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J. Exp. Med. 176 (1992) 1335-1341
22. Harlow E., Crawford L.V., Pim D.C., and Williamson N.M. Monoclonal antibodies specific for Simian virus 40 tumor antigens. J. Virol. 39 (1981) 861-869
23. Hiscott J., Murphy D., and Defendi V. Amplification and rearrangement of integrated SV40 DNA sequences accompany the selection of anchorage-independent transformed mouse cells. Cell 22 2 Pt. 2 (1980) 535-543
24. Hiscott J.B., Murphy D., and Defendi V. Instability of integrated viral DNA in mouse cells transformed by Simian virus 40. Proc. Natl. Acad. Sci. U.S.A. 78 3 (1981) 1736-1740
25. Karre K., Ljunggren H.G., and Piontek G. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature (London) 319 (1986) 675-678
26. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3 11 (2002) 999-1005
27. Kierstead T.D., and Tevethia M.J. Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using Simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. J. Virol. 67 4 (1993) 1817-1829
28. Klenerman P., Wu Y., and Phillips R. HIV: current opinion in escapology. Curr. Opin. Microbiol. 5 (2002) 408
29. Lill N.L., Tevethia M.J., Hendrickson W.G., and Tevethia S.S. Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes. J. Exp. Med. 176 (1992) 449-457
30. b-restricted cytotoxic T-lymphocyte epitopes in Simian virus 40 tumor antigen. J. Virol. 69 5 (1995) 3134-3146
31. Ljunggren H.G., and Karre K. Host resistance directed selectively against H-2 deficient lymphoma variants. Analysis of mechanism. J. Exp. Med. 162 (1985) 1745-1759
32. Loftus D.J., Squarcina P., Nielsen M.B., Geisler C., Castelli C., Odum N., Appella E., Parmiani G., and Rivoltini L. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res. 58 (1998) 2433-2439
33. Manfredi J.J., and Prives C. The transforming activity of Simian virus 40 large tumor antigen. Biochem. Biophys. Acta 1198 (1994) 65-83
34. Mortara L., Letourneur F., Gras-Masse H., Venet A., Guillet J.G., and Bourgault-Villada I. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J. Virol. 72 (1998) 1403-1410
35. b-restricted Simian virus 40 large T antigen epitope I variant. J. Immunol. 162 (1999) 2171-2179
36. b-restricted cytotoxic T-lymphocyte epitopes within Simian virus 40 T antigen. J. Virol. 69 11 (1995) 6665-6677
37. b-restricted determinant in Simian virus 40 tumor antigen. Virology 208 (1995) 159-172
38. Mylin L.M., Schell T.D., Roberts D., Epler M., Boesteanu A., Collins E.J., Frelinger J.A., Joyce S., and Tevethia S.S. Quantitation of CD8+ T-lymphocyte responses to multiple epitopes from Simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J. Virol. 74 (2000) 6922-6934
39. Pewe L., and Perlman S. Immune response to the immunodominant epitope of mouse hepatitis virus is polyclonal, but functionally monospecific in C57Bl/6 mice. Virology 255 (1999) 106-116
40. Potter T.A., Boyer C., Verhulst A.M., Golstein P., and Rajan T.V. Expression of H-2Db on the cell surface in the absence of detectable b-2 microglobulin. J. Exp. Med. 160 (1984) 317-322
41. Ryan C.M., and Schell T.D. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J. Immunol. 177 (2006) 255-267
42. Salvucci L.A., Bonneau R.H., and Tevethia S.S. Polymorphism within the herpes simplex virus type I (HSV-1) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV-1 specific cytotoxic T lymphocytes. J. Virol. 69 (1995) 1122-1131
43. Schell T.D. In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in Simian virus 40 T-antigen-transgenic mice. J. Virol. 78 (2004) 1751-1762
44. Schell T.D., and Tevethia S.S. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8+ T lymphocytes by the endogenous tumor antigen. J. Immunol. 167 (2001) 6947-6956
45. Schell T.D., Mylin L.M., Georgoff I., Teresky A.K., Levine A.J., and Tevethia S.S. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in Simian virus 40 large T antigen transgenic mice. J. Virol. 73 (1999) 5981-5993
46. Schell T.D., Knowles B.B., and Tevethia S.S. Sequential loss of cytotoxic T lymphocyte responses to Simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res. 60 (2000) 3002-3012
47. Shastri N., Serwold T., and Gonzalez F. Presentation of endogenous peptide/MHC complexes is profoundly influenced by specific C-terminal flanking residues. J. Immunol. 155 (1995) 4339-4352
48. Staveley-O'Carroll K., Schell T.D., Jimenez M., Mylin L.M., Tevethia M.J., Schoenberger S.P., and Tevethia S.S. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J. Immunol. 171 2 (2003) 697-707
49. Tanaka Y., and Tevethia S.S. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J. Immunol. 140 12 (1988) 4348-4354
50. Tanaka Y., and Tevethia S.S. Loss of immunorecessive cytotoxic T lymphocyte determinant V on SV40 T antigen following cocultivation with site-specific cytotoxic T lymphocyte clone Y-5. Intervirology 31 (1990) 197-202
51. Tanaka Y., Tevethia M.J., Kalderon D., Smith A.E., and Tevethia S.S. Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virology 162 (1988) 427-436
52. b-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology 171 (1989) 205-213
53. Tevethia M.J. Immortalization of primary mouse embryo fibroblasts with SV40 virions, viral DNA, and a subgenomic DNA fragment in a quantitative assay. Virology 137 (1984) 414-421
54. Tevethia S.S., Flyer D.C., and Tjian R. Biology of Simian Virus 40 (SV40) transplantation antigen (TrAg): VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein). Virology 107 (1980) 13-23
55. Tevethia S.S., Mylin L., Newmaster R., Epler M., Lednicky J.A., Butel J.S., and Tevethia M.J. Cytotoxic T lymphocyte recognition sequences as markers for distinguishing among tumour antigens encoded by SV40, BKV, and JCV. Dev. Biol. Stand. 94 (1998) 329-339
56. Tevethia S.S., Beachy T., Schell T., Lippolis J., Newmaster R., Mylin L., and Tevethia M.J. Role of CTL host responses and their implication for tumorigenicity testing and the use of tumour cells as vaccine substrate. Dev. Biol. Stand. 106 (2001) 109-121
57. Theobald M., Ruppert T., Kuckelhorn U., Hernzndez J., Haussler A., Ferreira E.A., Liewer U., Biggs J., Levine A.J., Huber C., Kozinowski U.H., Kloetzel P.M., and Sherman L.A. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med. 188 (1998) 1017-1028
58. Thompson D.L., Kalderon D., Smith A.E., and Tevethia M.J. Dissociation of Rb-binding and anchorage-independent growth from immortalization and tumorigenicity using SV40 mutants producing N-terminally truncated large T antigens. Virology 178 (1990) 15-34
59. Turner S.J., and Carbone F.R. A dominant V beta bias in the CTL response after HSV-1 infection is determined by peptide residues predicted to also interact with the TCR beta-chain CDR3. Mol. Immunol. 35 (1998) 307-316
60. Wiesmuller L., Cammenga J., and Deppert W.W. In vivo assay of p53 function in homologous recombination between Simian virus 40 chromosomes. J. Virol. 70 (1996) 737-744
61. Yanisch-Perron C., Vieira J., and Messing J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33 (1985) 103-119
62. Yellen-Shaw A.J., and Eisenlohr L.C. Regulation of class I-restricted epitope processing by local or distal flanking residues. J. Immunol. 158 (1997) 1727-1733
63. Yellen-Shaw A.J., Wherry E.J., Dubois G.C., and Eisenlohr L.C. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J. Immunol. 158 (1997) 3227-3234
64. b at 2.4 A resolution: implications for antigen-determinant selection. Cell 76 1 (1994) 39-50